The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

Akpinar S., Dogu M. H., ÇELİK S., Ekinci O., Hindilerden I. Y., Dal M. S., ...More

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.22, no.3, pp.169-173, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 3
  • Publication Date: 2022
  • Doi Number: 10.1016/j.clml.2021.09.010
  • Journal Name: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.169-173
  • Keywords: Chronic lymphocytic leukemia, Bruton tyrosine kinase, Ibrutinib, Relapsed/refractory, p53 mutation
  • Erciyes University Affiliated: Yes

Abstract

We evaluated the safety and efficacy of single-agent ibrutinib in 200 patients presenting with relapsed/refractory CLL in real-world settings. With an estimated median OS of 52 months, 146 patients (75%) achieved at least PR; 16 (8.7%) patients discontinued ibrutinib due to adverse events. The results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice.